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ABSTRACT
Introduction. The pathogenesis of type 2 diabetes mel-
litus (T2DM) is strongly linked to oxidative stress mainly 
caused by chronic hyperglycaemia. The present study 
investigates the association between hyperglycaemia 
with oxidative stress markers, antioxidants and lipid 
profile.
Materials and methods. The case-control study in-
volved two groups, T2DM patients (n = 83) and age 
and sex matched controls (n = 81). Serum levels of 
various molecular markers malondialdehyde (MDA), 
reactive oxygen species (ROS) and nitric oxide (NO), su-
peroxide dismutase (SOD), catalase (CAT), glutathione 
(GSH), vitamin C, total antioxidant capacity (TAC) and 
lipid parameters total cholesterol, triglycerides, low 
density lipoprotein (LDL) and high density lipoprotein 
(HDL) were measured using spectrophotometric as-
says. Results were analysed to compare and correlate 
glycaemic levels with these molecular markers. 
Results. T2DM patients had a higher body mass index 
(BMI) and body fat percentage. 2 hour blood glucose, 
glycated haemoglobin A1c % (HbA1c), total cholesterol, 
triglycerides and LDL were higher in diabetics, HDL 
was found to be lower in diabetics than in controls. 
Mean levels of enzymatic and non-enzymatic antioxi-
dants SOD, CAT, GSH, vitamin C and TAC were signifi-
cantly lower while oxidative stress markers NO, ROS 
and MDA were higher in T2DM patients. NO showed 
a positive correlation (r = 0.3993, p < 0.0001) whereas 
TAC showed a negative correlation with glycaemia 
(r = –0.4796, p < 0.0001). 
Conclusions. Poor glycaemic control in T2DM causes 
elevated ROS and NO levels with increased lipid peroxi-
dation and lowered antioxidant capacity. MDA and NO 
being the major risk factors could be used as a param-
eter along with antioxidants to assess oxidative stress 
in T2DM patients. (Clin Diabetol 2019; 8, 4: 215–222)
Key words: total antioxidant capacity, nitric 
oxide, malondialdehyde, type 2 diabetes mellitus, 
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Introduction
Type 2 diabetes mellitus or non-insulin dependent 
diabetes mellitus (NIDDM) is a metabolic syndrome of 
multiple etiology characterised by chronic hyperglycae-
mia resulting from disturbances in glucose and lipid 
metabolism. Diabetes causes an array of microvascular 
and macrovascular complications and stroke with an 
increasing incidences worldwide. The various diabetic 
complications, b-cell dysfunction and worsening of 
glycaemic control is linked to increased reactive oxida-
tive stress (ROS) and reactive nitrosative stress (RNS) 
owing to increased production of free radicals such as 
the nitric oxide, superoxide radical, hydrogen peroxide 
and the hydroxide radical and free radical induced 
lipid peroxidation and a deficiency in the antioxidant 
defence mechanisms. The lipid peroxidation of tissues 
which is primarily caused due to increased ROS, is 
thought to play an important role in the development 
of atherosclerosis and other microvascular complica-
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tions [1]. During the development of the disease, 
hyperglycemia causes increase in production of ROS 
in different tissues by forming advanced glycation end 
products. Hyperglycaemia-induced mitochondrial su-
peroxide production is the sole underlying mechanism 
by which it induces cellular damage. The antioxidant 
defence network maintains the mitochondrial level 
of ROS within balanced concentrations. However, in 
hyperglycemia environment, enhanced glucose flux 
through glycolysis and Krebs cycle causes an overdrive 
of mitochondrial electron transport chain (ETC) result-
ing in mitochondrial dysfunction and increased ROS 
formation [2]. Excessive levels of ROS leads to cellular 
dysfunction, altered cell cycle, altered cell-signalling, in-
creased inflammation and also is linked to development 
of insulin resistance, impaired metabolic pathways, 
diabetes and cardiovascular disorders (CVD) through 
dysfunction of insulin secretion and metabolism. An-
tioxidant defence mechanisms involve both enzymatic 
and non-enzymatic strategies. Common antioxidants 
include vitamin A, C and E, non-enzymatic antioxidant 
and cofactor GSH (L-g-glutamyl-L-cysteinylglycine) and 
the enzymes superoxide dismutase (SOD), catalase 
(CAT) and glutathione peroxidase (GPx). They work in 
synergy with each other and against different types of 
free radicals [3]. The impairment of the endogenous 
antioxidant defence system is produced in many ways 
during chronic hyperglycaemia. 
Lipids with unsaturated double bonds are highly 
susceptible to damage by free radicals, this process 
is commonly known as lipid peroxidation and it has 
deleterious effects in the biological system and it has 
been strongly linked to diabetes pathogenesis and com-
plications. Malondialdehyde (MDA) is formed as an end 
product of lipid peroxidation. Elevated MDA levels show 
adverse physiological consequences which include al-
tering cell membrane structural integrity, inactivating 
membrane bound enzymes and cell surface receptors. 
MDA is involved in foam cell formation which leads to 
atherosclerosis and other cardiovascular diseases. The 
determination of MDA is an important parameter to 
evaluate in vivo lipid peroxidation [4]. Nitric oxide (NO) 
is a gaseous free radical synthesized as a by-product 
from L-arginine to L-citrulline conversion by the action 
of nitric oxide synthase (NOS). Endotoxins and cytokines 
produce an inflammatory response which expresses 
NOS II, which can generate excess endogenous NO over 
long periods further aggravating inflammatory and 
ischemic processes. NO plays a role in angiogenesis, 
neurotoxicity and is involved in mediating diabetic 
retinal vascular injury which suggests the possible role 
of NO in pathogenesis of diabetic retinopathy (DR) [5]. 
The collective action of all the antioxidants present in 
plasma and other body fluids can be defined as the total 
antioxidant capacity (TAC) which provides a composed 
parameter instead of a sum of all antioxidants. Altera-
tions in TAC levels show a significant role in metabolic 
syndrome (MetS) and gestational diabetes [6].
Materials and methods
Subjects and study design
The present study was conducted in Department 
of Studies in Zoology, University of Mysore, Karnataka, 
India during the period of January–July 2018. The 
study conformed to the Helsinki declaration and was 
conducted with the approval of the Institutional ethi-
cal and research committee. 83 T2DM patients were 
recruited from an outpatient department of medicine 
of a primary health centre. For comparison, 81 age and 
sex matched healthy controls were randomly selected 
and recruited. Diagnosis for T2DM was done according 
to World Health Organisation (WHO) recommendations 
for the diagnostic criteria for diabetes and intermedia-
te hyperglycaemia (2006). Inclusion criteria for T2DM 
patients included age group of 25–60, 2 hour blood 
glucose ≥ 11.1 mmol/L and treatment with hypogly-
caemic drugs. Exclusion criteria included patients using 
any kind of vitamin supplements, lipid lowering drugs, 
antioxidant supplements, anti-inflammatory drugs, 
pregnant and lactating women, alcoholics, smokers 
and individuals with tobacco and other drug addic-
tion, past history of chronic illness like tuberculosis, 
autoimmune disorders, endocrine disorders, patients 
with type 1 DM and any patient who did not meet 
the inclusion criteria were excluded from study group. 
Criteria for controls were based on previous medical 
and family history of diabetes, free of any metabolic 
disorders and other major diseases and 2 h blood 
glucose < 11.1 mmol/L. 
Assessment of biochemical parameters
Venous blood samples was drawn to analyse 2 hour 
blood glucose and the serum was used to analyse HbA1c 
and lipid parameters. The serum was stored at –20°C for 
further analysis of molecular markers. All the biochemi-
cal estimations were done with the spectrophotometer 
Varioskan LUX multimode microplate reader instrument 
(ThermoFisher Scientific, USA). 2 h glucose in blood 
was estimated by GOD-POD technique. The lipid profile 
estimation was done using Arkray (Arkray healthcare, 
Mumbai, India) lipid kit. Serum total cholesterol (TC) 
was estimated by CHOD-PAP method. Serum HDL was 
estimated with the HDL precipitation reagent and a 
HDL standard using the CHOD-PAP kit. Triglycerides 
(TG) was estimated using GPO-PAP technique. LDL was 
measured indirectly using the Friedewald formula [7]. 
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Assessment of obesity parameters
The BMI were calculated by dividing weight in kilo-
grams by the square of the height in metres [kg/m2]. 
The body fat percentage were measured using OMRON 
HBF-306 body fat monitor. The Asian Indian criteria of 
obesity and overweight was used to define the BMI in 
the subjects (normal BMI: 18.0–22.9 kg/m2, overweight: 
23.0–24.9 kg/m2, obesity: > 25 kg/m2) [8]. 
Molecular markers analysis 
The total serum proteins were measured by Lowry 
method using bovine serum albumin as the standard. 
SOD activity was measured spectrophotometrically us-
ing Fridovich et al. [9] method where photo reduction 
of riboflavin leading to nitrite formation was measured 
at 543 nm. Serum Glutathione (GSH) was measured 
by its reaction with 5-5’ dithiobis (2-nitrobenzoic 
acid) (DTNB) to give a yellow coloured complex whose 
absorbance is measured at 412 nm [10]. CAT activity 
was measured spectrophotmetrically by following the 
oxidation of H2O2 at 240 nm. The decomposition of 
H2O
2 can be followed directly by decrease in absorb-
ance at 240 nm. The difference in absorption per unit 
time is the measure of catalase activity [11]. Vitamin C 
in serum was determined by dinitrophenyl hydrazine 
method where ascorbic acid is oxidized to form a 
coloured complex which is measured at 520 nm. TAC 
was determined spectrophotometrically through the 
formation of phosphomolybdenum complex. 100 μL 
of serum was mixed with 100 μL of 5% trichloroacetic 
acid (TCA) to precipitate the proteins. The sample was 
centrifuged and the supernatant was reacted with 1ml 
of TAC reagent (0.6 M sulphuric acid, 28 mM sodium 
phosphate, and 4 mM ammonium molybdate) which 
was incubated at 95°C for 90 minutes. The samples 
were cooled to room temperature and the absorbance 
of the aqueous solution was read at 695 nm against a 
blank [12]. The lipid peroxidation product, MDA, was 
measured by using thiobarbituric acid reactive sub-
stances (TBARS). MDA reacts with thiobarbituric acid 
at 100°C in an acidic medium to give a pink coloured 
complex. The colour intensity of the MDA-TBA complex 
was measured at 535 nm by using a spectrophotom-
eter [13]. Serum NO was measured using the Griess 
reaction using a modified method of Grisham et al. 
[14]. Equal volumes of the serum sample and freshly 
prepared Griess reagent were incubated at 37°C for 
10 minutes. A stable decomposition product (NO2–) 
formed the coloured complex and its absorbance was 
measured at 540 nm using a spectrophotometer. ROS 
was measured fluorometrically using the dichlorofluo-
rescindiacetyl (DCFDA) oxidation method by determin-
ing the hydrogen peroxide concentrations present in 
serum [15]. ROS oxidises DCFDA into a fluorescent 
compound dichlorofluoroscein (DCF). The fluorescence 
emitted was determined using a fluorometric reader 
(Varioskan LUX multimode microplate reader) at an 
excitation wavelength of 525 nm and an emission 
wavelength of 488 nm. 
Statistical analysis 
The subjects were grouped into T2DM (n = 83) and 
controls (n = 81). The difference in various parameters 
like age, body mass index, diabetes duration, glycaemic 
levels, lipid profiles and molecular markers were tested 
for significance by comparing the two groups using 
student t-test and the relationship of family history 
with DM was assessed using chi-square test. The asso-
ciation between hyperglycaemia and diabetes duration 
with various clinical factors were assessed using linear 
regression analysis. BMI and Age were entered in the 
multiple regression analysis model to determine its 
association with glycaemic status. Pearson’s correla-
tion coefficient was used to determine the relation-
ship between glycaemic levels and serum NO and TAC 
levels. All the data were entered in a Microsoft excel 
spreadsheet. Statistical analysis was performed using 
IBM SPSS version 23.0 (SPSS, Chicago, IL, USA) and 
GraphPad Prism version 6.0 (GraphPad Software, San 
Diego, CA, USA). Data are reported as mean ± standard 
deviation (mean ± SD). The level of significance for all 
tests was set at p < 0.05. 
Results
Individuals with T2DM were older compared to 
non-diabetics (p < 0.0001). T2DM patients also had 
a higher rate of diabetes in family history. The BMI 
(p < 0.0001) and body fat percentage (p < 0.0001) 
were higher in T2DM when compared to the controls. 
The average DM duration for the whole sample was 
9.0 ± 3.1 years, females had a higher DM duration 
than males (Table 1). The diabetic patients in the study 
were either undergoing treatment with metformin only 
(n = 33) or no treatment at all (n = 50). There was 
no statistically significant difference observed in the 
levels of various parameters between the treatment 
and non-treatment groups. The 2-hr blood glucose 
(p < 0.0001), HbA1c% (p < 0.0001), total cholesterol 
(p < 0.0001), triglycerides (p < 0.001) and LDL (p < 0.019) 
were higher in diabetics when compared to controls 
while serum HDL (p < 0.002) was found to be lower in 
diabetics than in controls (Table 2). Mean levels of enzy-
matic and non-enzymatic antioxidants SOD (p = 0.045), 
CAT (p < 0.0001), GSH (p < 0.0001), vitamin C 
(p < 0.001) and total antioxidant capacity (p < 0.0001) 
were significantly lower in T2DM patients compared 
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to controls. Oxidative stress markers NO (p < 0.0001), 
ROS (p = 0.007) and MDA (p < 0.0001) were higher 
in T2DM patients when compared to controls (Table 3). 
Linear regression analysis showed a positive asso-
ciation between hyperglycaemia and oxidative stress 
markers, BMI, total cholesterol, triglycerides and LDL 
and negative association with antioxidant levels and 
HDL (Table 4). There was no correlation observed 
between diabetes duration with different molecular 
markers and lipid profile, a positive association between 
diabetes duration and glycaemic levels, BMI and fat % 
whereas a negative association with TAC was observed 
(Table 5). Multiple regression analysis was used to 
test if age and BMI significantly affects the glycaemic 
status in T2DM patients. The results of the regression 
indicated the two predictors explained 7.3% of the 
variance [R2 = 0.073, F(2,161) = 6.34, p = 0.002]. 
It was found that BMI significantly affected glucose 
Table 1. Demographic characteristics of the patients
Parameter Total (n = 164) Type-2 diabetics (n = 83) Controls (n = 81) p
Age (years) 48.1 ± 8.8 50.0 ± 8.3 46.1 ± 8.9 0.0001
Sex ratio (M/F) 99/65 50/33 49/32 0.9092
Family history of T2DM (yes/no) 44/120 32/51 12/69 0.0007
Diabetes duration in years – – 0.0001
a. Male a. 9.6 ± 3.7 
b. Female b.  8.6 ± 2.5
BMI [kg/m2] 27.0 ± 4.1 28.1 ± 4.1 25.9 ± 3.9 0.0001
Body fat (%) 31.3 ± 6.6 33.1 ± 5.8 29.5 ± 6.9 0.0001
 Data presented as mean ± SD. T2DM — type 2 diabetes mellitus; BMI — body mass index
Table 2. Biochemical parameters
Parameter Type 2 diabetics Controls 95% CI p
2-hr blood glucose [mmol/L] 14.25 ± 4.46 6.29 ± 1.21 6.94, 8.96 0.0001
HbA1c (%) 10.57 ± 2.80 5.57 ± 0.76 4.36, 5.63 0.0001
Total cholesterol [mg/dL] 159.72 ± 38.69 117.48 ± 32.21 31.32, 53.14 0.0001
Triglycerides [mg/dL] 151.37 ± 48.89 126.0 ± 30.59 10.09, 40.64 0.002
LDL [mg/dL] 58.72 ± 21.40 45.85 ± 30.30 2.26, 23.47 0.019
HDL [mg/dL] 44.44 ± 9.53 48.66 ± 9.31 1.10, 7.33 0.002
Total serum proteins [mg/dL] 6.45 ± 3.80 8.95 ± 3.31 1.37, 3.62 0.0001
Data presented as mean ± SD. HbA1c — glycated haemoglobin; LDL— low density lipoprotein cholesterol; HDL — high density lipoprotein cholesterol; 95% 
CI — 95% confidence intervals; CI here indicates difference between two population means lies between lower CI and upper CI
Table 3. Oxidative stress and antioxidant parameters
Parameter Type 2 diabetics Controls 95% CI p
SOD [units/mg protein] 0.0602 ± 0.108 0.1008 ± 0.128 0.001, 0.080 0.045
CAT [nmol H2O2 oxidised/min/mL] 0.0284 ± 0.0298 0.0481 ± 0.0350 0.01, 0.03 0.0001
GSH [nmol/mL] 23.316 ± 0.584 24.593 ± 1.120 0.705, 1.849 0.0001
Vitamic C [μmol/L] 31.001 ± 8.693 55.992 ± 18.691 15.957, 34.025 0.0001
TAC [μmol a-tocopherol/L] 119.977 ± 44.103 160.793 ± 60.302 18.985, 62.649 0.0001
Serum NO [μmoles/L] 72.170 ± 26.021 47.022 ± 23.607 17.539, 32.757 0.0001
ROS [mmol DCF formed/min/mg protein] 0.474 ± 0.241 0.388 ± 0.128 0.025, 0.147 0.007
Serum MDA [nmol/mg protein] 0.304 ± 0.178 0.178 ± 0.141 0.076, 0.177 0.0001
Data presented as mean ± SD. SOD — superoxide dismutase; CAT — catalase; GSH — reduced glutathione; TAC — total antioxidant capacity; NO — nitric 
Oxide; ROS — reactive oxygen species; MDA — malondialdehyde; 95% CI — 95% confidence intervals; CI here indicates difference between two population 
means lies between lower CI and upper CI
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levels (b = 0.207, p = 0.007) as well as age (b = 0.184, 
p = 0.017). Glycaemic levels showed a significant 
negative correlation with total antioxidant status 
(r = –0.4796, p < 0.0001) (Figure 1A), whereas glycae-
mic levels showed a significant positive correlation with 
oxidative stress marker NO (r = 0.3993, p < 0.0001) 
(Figure 1B). 
Discussion
Oxidative stress has focus interest in various clinical 
research in recent times. There is a growing evidence 
connecting the action of oxidative stress to the patho-
genesis and complications in diabetes mellitus and 
many other diseases. Oxidative stress plays a role in 
pathogenesis of insulin resistance and b-cell dysfunc-
Table 4. Association of hyperglycaemia with different parameters
Parameter *R2 Slope 95% CI F p
Age 0.0194 0.2395 ± 0.1335 –0.0220, 0.5011 3.221 0.0746
BMI 0.0328 0.1461 ± 0.0623 0.0239, 0.2682 5.497 0.0203
Fat % 0.0316 0.2285 ± 0.0993 0.0337, 0.4231 5.290 0.0227
Cholesterol 0.1629 3.233 ± 0.5758 2.105, 4.362 31.53 0.0001
HDL 0.0952 –0.666 ± 0.1731 –1.006, –0.3276 14.84 0.0002
LDL 0.0642 1.482 ± 0.5601 0.3699, 2.595 7.003 0.0094
TG 0.0564 2.072 ± 0.8391 0.4058, 3.739 6.099 0.0152
CAT 0.0675 –0.0017 ± 0.0004 –0.0026, –0.0007 11.74 0.0008
SOD 0.0347 –0.0048 ± 0.0021 –0.0090, –0.0006 5.143 0.0248
GSH 0.1552 –0.1022 ± 0.0324 –0.1673, –0.0370 9.918 0.0027
Vitamin C 0.1298 –0.3521 ± 0.1479 –0.6517, –0.0525 5.667 0.0224
TAC 0.1558 –5.009 ± 1.138 –7.268 to –2.750 19.37 0.0001
ROS 0.0497 0.0090 ± 0.0033 0.002512, 0.01551 7.384 0.0074
NO 0.1304 1.945 ± 0.3945 1.172 to 2.718 24.30 0.0001
MDA 0.0500 0.0074 ± 0.0026 0.0023, 0.0125 8.055 0.0052
*Linear regression analysis — goodness of fit. 95% CI — 95% confidence intervals; BMI — body mass index; TG: — triglycerides; LDL — low density lipo-
protein cholesterol; HDL — high density lipoprotein cholesterol; SOD — superoxide dismutase; CAT — catalase; GSH — reduced glutathione; TAC — total 
antioxidant capacity; NO — nitric oxide; ROS — reactive oxygen species; MDA — malondialdehyde
Table 5. Association of diabetes duration with different parameters
Parameter *R2 Slope 95% CI F p
Glucose 0.5537 1.092 ± 0.1089 0.8745, 1.309 100.5 0.0001
BMI 0.0472 0.2940 ± 0.1467 0.0015, 0.5864 4.015 0.0484
Fat % 0.059 0.4664 ± 0.2070 0.05392, 0.8789 5.078 0.0269
Cholesterol 0.0185 1.730 ± 1.399 –1.059, 4.519 1.529 0.2199
HDL 0.0055 –0.2809 ± 0.4835 –1.248, 0.6861 0.3375 0.5635
LDL 0.0243 1.390 ± 1.393 –1.425, 4.205 0.9960 0.3243
TG 0.0158 2.718 ± 3.391 –4.135, 9.570 0.6425 0.4276
CAT 0.0057 –0.0007 ± 0.0010 –0.0029, 0.0014 0.4694 0.4952
SOD 0.0386 –0.0091 ± 0.0057 –0.0206, 0.0024 2.495 0.1193
GSH 0.0398 –0.0866 ± 0.0699 –0.2284, 0.0551 1.535 0.2231
Vitamin C 0.0382 –0.0712 ± 0.0842 –0.2483, 0.1057 0.7161 0.4085
TAC 0.2906 –8.923 ± 2.323 –13.64, –4.208 14.75 0.0005
ROS 0.0139 0.0059 ± 0.0064 –0.0069, 0.0187 0.8504 0.3601
NO 0.0048 0.5972 ± 0.9477 –1.292, 2.486 0.3971 0.5304
MDA 0.0095 0.0058 ± 0.0069 –0.0080, 0.0198 0.7128 0.4012
*Linear regression analysis — goodness of fit. 95% CI — 95% confidence intervals; BMI — body mass index; TG — triglycerides LDL — low density lipo-
protein cholesterol; HDL — high density lipoprotein cholesterol; SOD — Superoxide dismutase; CAT — Catalase; GSH — reduced glutathione; TAC — total 
antioxidant capacity; NO — nitric oxide; ROS — reactive oxygen species; MDA — malondialdehyde
Clinical Diabetology 2019, Vol. 8, No. 4
220
cholesterol concentrations. Dyslipidaemia is attributed 
to free fatty acid flux secondary to insulin resistance 
[18]. Data from table 2 shows a considerable increase 
in total cholesterol, serum triglycerides and LDL levels 
and a significant decrease in HDL levels in this study 
indicating a dyslipidaemia condition in the diabetic 
patients although the LDL and triglyceride parameters 
in diabetics do not exceed the American Diabetes As-
sociation 2011 guidelines for lipid goals [19]. Dyslipi-
daemia in diabetes have the ability to generate oxida-
tive stress which possibly leads to the development of 
macroangiopathy causing endothelial dysfunction and 
atherosclerosis. 
The study also showed a significant drop in both 
enzymatic and non-enzymatic antioxidants. There was 
a drop in serum CAT activity which was in agreement 
with the findings of Pasaoglu et al. [20]. Several studies 
on serum and erythrocyte SOD levels have shown in-
creased, decreased as well as unchanged enzyme levels. 
In this study there was a decrease in SOD activity. This 
finding is in accordance with Kesavulu et al. We observe 
a decrease in CAT activity and consequently SOD activ-
ity. A possible explanation for the fall in SOD activity 
could be linked to glycation of the SOD enzyme in se-
rum due to hyperglycaemic condition. Decrease in SOD 
activity consequently leads to decrease in CAT activity 
as both the enzymes function in unison to neutralise 
superoxide ion to water and oxygen molecule [21]. 
Another possible explanation for the fall in CAT activity 
could be due to downregulation of serum CAT due to 
catalase gene mutations caused by elevated hydrogen 
peroxide levels [22]. The study also observed decrease 
in serum GSH levels which was consistent with that of 
Gallou et al. [23]. GSH a key intracellular antioxidant 
is involved in redox regulation of protein thiols and 
hydrogen peroxide in mitochondria [21]. Several studies 
have shown that reduced/oxidized glutathione ratio is 
lower in diabetics [24]. In hyperglycaemic conditions, 
glucose is preferentially used in polyol pathway which 
consumes NADPH that is necessary for GSH regulation 
by the GR enzyme. Thus, hyperglycaemia indirectly 
causes GSH depletion. Vitamin C is a powerful dietary 
antioxidant, it donates electrons thus helping in scav-
enging free radicals. Vitamin C reduces the overall hy-
perglycaemic state by reducing blood glucose, reducing 
glycosylation of proteins and by decreasing the produc-
tion of sorbitol. Several clinical studies have shown 
that vitamin C levels in diabetics are lowered and that 
supplementing with vitamin drugs helps to slightly al-
leviate the diabetic complications [25]. In this study, the 
level of vitamin C, is significantly decreased in diabetics. 
A possible explanation for the low vitamin C levels in 
diabetics could be linked to increased ascorbic acid 
Figure 1A. Correlation between total antioxidant capacity 
(TAC) and blood glucose; B. Correlation between serum nitric 
oxide (NO) and blood glucose
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tion, caused by dysregulation of cell homeostasis 
and metabolism [4]. Hyperglycaemia is the principal 
metabolic alteration which is associated with diabetes 
mellitus, and increased glycaemic levels in bodily fluids 
has been implicated to increase oxidants, cause cellular 
damage, vascular dysfunction and pathogenesis of 
vascular disease. 
This study reveals a detailed information on the 
impact of hyperglycaemia on oxidative stress status 
in T2DM patients. Present study shows a two-fold 
higher blood glucose as well as HbA1c levels in diabetic 
compared to normal subjects, which is an indication of 
worsening glycaemic control. Hyperglycemia increases 
the levels of free radical generation which activates 
several pathways involved in pathogenesis of com-
plications of diabetes: polyol pathway, increased AGE 
formation and activation of protein kinase C (PKC) iso-
forms [16]. This ultimately leads to irreversible damage 
of biomolecules like proteins, lipids and nucleic acids 
and loss of its functional ability [17]. Dyslipidaemia is a 
major risk factor for CVD in diabetes mellitus. It is char-
acterised by high total cholesterol, serum triglyceride 
concentrations, high LDL cholesterol and lowered HDL 
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oxidation or impaired regeneration from its oxidized 
state [21]. There has been limited studies describing the 
total antioxidant status in T2DM. This study concluded 
that diabetics had a lower TAC level than controls. The 
correlation study showed that TAC was negatively corre-
lated with glycaemic levels indicating worsening plasma 
antioxidant capacity with increased hyperglycaemia in 
T2DM. Opara et al. observed a decrease in TAC levels 
in diabetic patients whereas Korkmaz et al. observed 
increased TAC levels in early diabetic stages and Savu 
et al. observed an increase in TAC levels synergistically 
with other antioxidants as well as MDA [25–27]. As 
the results stand controversial and the mechanisms are 
poorly understood, further investigation is needed to 
validate the status of TAC for monitoring antioxidant 
levels in diabetes. 
T2DM is characterised by prolonged and increased 
intracellular and extracellular ROS generation. In this 
study ROS levels were studied by determining the perox-
ide concentrations in serum. The ROS levels in diabetics 
were slightly higher than in controls although there was 
no significant difference between them. Free radicals 
attack membrane phospholipids causing lipid peroxi-
dation and high levels of these oxidised products have 
been correlated with development of vascular compli-
cations. The high levels of MDA in serum can be linked 
to failure of antioxidant system to curb the deleterious 
action of free radicals and hence it serves as a reliable 
stress marker to assess free radical induced tissue dam-
age [7]. The increase in lipid peroxidation reflected by 
the increase in serum MDA levels in diabetics in the 
present study are in accordance with previous studies 
that hyperglycaemia increases lipid peroxidation from 
overproduction of free radicals in diabetics [20]. The 
study showed significantly higher levels of serum NO in 
T2DM patients than in controls. Additionally, NO levels 
were positively correlated with increasing glucose levels 
which shows worsening glycaemic control accelerates 
NO production in serum. These findings are in agree-
ment with Maejima et al. and Ozden et al. [28, 29]. 
Ozden et al. explains increased NO synthesis is a result 
of compensatory mechanism due to oxidative stress 
causing NO inactivation by inhibiting NO mediated 
endothelial function. Contrary to this study, Ghosh et al. 
reported decreased serum NO levels in T2DM patients 
[30]. Elevated serum NO levels have been attributed 
to pathogenesis of diabetes and diabetic retinopathy, 
hence assessing NO levels could be an important tool 
to measure the severity of diabetes in patients. 
The regression analysis shows hyperglycaemia to be 
strongly associated with obesity and CVD-risk param-
eters showing a positive association with BMI, body fat, 
total cholesterol and LDL. It also showed a strong posi-
tive association with MDA and NO levels and a negative 
association with CAT, GSH, vitamin C and TAC levels. 
In contrast, diabetes duration and oxidative stress pa-
rameters and lipid profile showed no correlation. This 
finding is consistent with the results of Aouacheri et al. 
[31]. The positive association between diabetes dura-
tion with glycaemic levels and negative association with 
TAC in the analysis indicates prolonged hyperglycaemic 
conditions greatly reduces the antioxidant capacity of 
cells, leading to oxidative stress. This study shows that 
poor glycaemic control in T2DM elevates oxidative and 
nitrosative factors, decreases antioxidants and alters 
lipid profile all of which are strongly linked to diabetic 
and vascular complications. 
Conclusions
This study shows the importance of monitoring 
levels of antioxidants in parallel with NO and MDA along 
with the usual glycaemic and lipid markers in T2DM 
which could be useful to assess the degree of oxidative 
stress present and provide important identification cues 
for patients to undergo antioxidant treatment since 
administration of antioxidants is found to be effective 
only in selective group of patients with depleted natural 
antioxidants and elevated oxidative stress levels. Some 
of the limitations of this study are the small patient 
population to assess the different parameters and the 
need to perform assays on protein carbonyls to further 
understand the extent of damage caused by oxidative 
stress in T2DM. More clinical studies are needed on larger 
patient populations to understand the underlying phy-
siological effects of ROS, RNS and different antioxidants 
in T2DM and the potential of using these parameters to 
determine oxidative stress in the patients.
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